
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
This patent covers technology developed by Tevogen.AI that leverages machine learning algorithms, powered by Microsoft (Nasdaq: MSFT ) and Databricks intended to rapidly and accurately identify peptides with strong immune system interactions. Identifying these peptides is critical in developing targeted therapies for a variety of diseases, including cancers and infectious diseases.
Traditional methods for identifying immunologically active peptides often face significant limitations, such as overlooking critical human genetic diversity factors like age, sex, race, and ethnicity. Tevogen.AI's proprietary approach may overcome these challenges by:
'I'm pleased with Tevogen.AI's continued progress in strategically harnessing artificial intelligence in support of our cell therapy development,' said Dr. Ryan Saadi, Founder and CEO of Tevogen. 'Leveraging AI to accelerate discovery, shorten development timelines, and reduce costs is essential to our mission of delivering commercially attractive, economically viable, and cost-effective personalized T cell therapies.'
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
[email protected]
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Multiple Tailwinds Send Fluor Corp. (FLR) Shares Higher
Hotchkis & Wiley, an investment management company, released its 'Hotchkis & Wiley Mid-Cap Value Fund' second quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter of 2025, equity market performance experienced significant volatility, primarily due to changes in U.S. trade policies and escalating geopolitical tensions. The fund lagged behind the Russell Midcap Value Index in the second quarter, gaining 3.63% vs 5.35% for the index. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second-quarter 2025 investor letter, Hotchkis & Wiley Mid-Cap Fund highlighted stocks such as Fluor Corporation (NYSE:FLR). Fluor Corporation (NYSE:FLR) is an engineering, procurement, and construction (EPC) company. The one-month return of Fluor Corporation (NYSE:FLR) was 8.76%, and its shares gained 16.40% of their value over the last 52 weeks. On July 29, 2025, Fluor Corporation (NYSE:FLR) stock closed at $55.99 per share with a market capitalization of $9.22 billion. Hotchkis & Wiley Mid-Cap Fund stated the following regarding Fluor Corporation (NYSE:FLR) in its second quarter 2025 investor letter: "Fluor Corporation (NYSE:FLR) is one of the largest contractors in the US. Unlike many competitors that specialize in elements of project delivery, most of Fluor's revenue comes from projects where it provides full Engineering, Procurement, and Construction (EPC) services. The company's shares rose in the quarter on improving margins and increased stock buyback guidance. Fluor is a high-quality professional services company with a medium-risk business model that grows with no reinvested capital. Valuation is extremely attractive on normal earnings and even more attractive if its NuScale small-scale nuclear reactor business realizes its potential." A close-up of an engineer surveying a large-scale construction project. Fluor Corporation (NYSE:FLR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 51 hedge fund portfolios held Fluor Corporation (NYSE:FLR) at the end of the first quarter, which was 48 in the previous quarter. While we acknowledge the potential of Fluor Corporation (NYSE:FLR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Fluor Corporation (NYSE:FLR) and shared the list of best undervalued stocks to invest in. Fluor Corporation (NYSE: FLR) was one of the largest individual detractors to the performance of the Hotchkis & Wiley Mid-Cap Fund in the previous quarter. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
Popular (BPOP) Surged in Q2 as Results Exceeded Expectations
Hotchkis & Wiley, an investment management company, released its 'Hotchkis & Wiley Mid-Cap Value Fund' second quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter of 2025, equity market performance experienced significant volatility, primarily due to changes in U.S. trade policies and escalating geopolitical tensions. The fund lagged behind the Russell Midcap Value Index in the second quarter, gaining 3.63% vs 5.35% for the index. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second-quarter 2025 investor letter, Hotchkis & Wiley Mid-Cap Fund highlighted stocks such as Popular, Inc. (NASDAQ:BPOP). Headquartered in Hato Rey, Puerto Rico, Popular, Inc. (NASDAQ:BPOP) is a banking and financial services company. The one-month return of Popular, Inc. (NASDAQ:BPOP) was 1.23%, and its shares gained 11.88% of their value over the last 52 weeks. On July 29, 2025, Popular, Inc. (NASDAQ:BPOP) stock closed at $114.82 per share, with a market capitalization of $7.801 billion. Hotchkis & Wiley Mid-Cap Fund stated the following regarding Popular, Inc. (NASDAQ:BPOP) in its second quarter 2025 investor letter: "Popular, Inc. (NASDAQ:BPOP), one of the largest banks in Puerto Rico, is a $65 billion asset bank with a dominant 45% market share of loans and deposits in the US territory. BPOP shares rose during the quarter after reporting earnings per share and net interest income results that were well ahead of consensus expectations. With its 45% market share in P.R. BPOP is a very well positioned and profitable bank with substantial excess capital. Trading at a low multiple of normal earnings per share (EPS) BPOP is an attractive value." A business executive in a suit working at their desk, surrounded by a busy office environment. Popular, Inc. (NASDAQ:BPOP) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held Popular, Inc. (NASDAQ:BPOP) at the end of the first quarter, which was 26 in the previous quarter. While we acknowledge the potential of Popular, Inc. (NASDAQ:BPOP) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
JPMorgan Partners With Coinbase To Expand Crypto Access For 80M Customers
JPMorgan Chase (NYSE:JPM), the largest U.S. bank with over $4 trillion in assets, has partnered with Coinbase (NASDAQ:COIN) to roll out a suite of crypto access features for its 80 million-plus customers, the companies announced on July 30. What Happened: Under the partnership, JPMorgan customers will soon be able to: Use Chase credit cards to fund Coinbase purchases, Redeem Chase Ultimate Rewards points for USDC, a U.S. dollar-pegged stablecoin, and Link Chase bank accounts directly to Coinbase for streamlined crypto transactions. Coinbase says the rollout will begin in fall 2025, with points-to-USDC redemption and bank integration scheduled for 2026. This collaboration signals growing comfort among major financial institutions in offering regulated access to crypto services. Also Read: Why It Matters: JPMorgan has previously maintained a cautious but steadily evolving approach to the crypto sector. CEO Jamie Dimon has publicly criticized Bitcoin (CRYPTO: BTC) in the past, but under his leadership, the firm has gradually integrated blockchain solutions and participated in digital asset pilots via Onyx, its blockchain division. In 2020, JPMorgan began providing banking services to Coinbase and Gemini, signaling an early move into the crypto sector. In May 2025, the bank settled its first transaction on a public blockchain, partnering with Chainlink (CRYPTO: LINK) and Ondo Finance (CRYPTO: ONDO). In June 2025, JPMorgan launched JPMD, a deposit token on Coinbase's Base blockchain, designed for institutional clients to facilitate 24/7 settlements and cross-border payments. The partnership with Coinbase, the largest publicly traded U.S. crypto exchange, brings JPMorgan's retail clients into direct contact with crypto markets through stablecoins, credit integration, and loyalty rewards. The new program will allow users to convert Chase Ultimate Rewards into USDC on Coinbase's Layer 2 network, Base, marking the first time a major U.S. rewards program has enabled point-to-crypto conversion. Coinbase described the collaboration as part of its broader effort to bridge traditional finance with crypto, offering seamless onramps for millions of users. Read Next: Image: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article JPMorgan Partners With Coinbase To Expand Crypto Access For 80M Customers originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.